Federal Grant Award Summary

The University of Washington received a $388,750 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective May 1, 2026 through April 30, 2031. This award supports fundamental research focused on bridging translational science gaps in drug pharmacokinetics and adverse drug reactions. The research program employs mechanistic in vitro studies, mass spectrometry-based proteomics experiments, and computational modeling to advance understanding of drug disposition, metabolism, and individual variability in drug responses across different patient populations.

The project deliverables include novel proteomics methodologies for characterizing drug-protein adduct formation, investigations into how drug-protein and protein-protein interactions alter drug distribution and metabolizing enzyme activity, and mechanistic assessments of how genetic variability and biological factors—including sex, disease status, and age—influence drug exposures in tissues and blood. By addressing key knowledge gaps in predicting drug exposures, drug-drug interactions, and susceptibility factors for adverse reactions, this research aims to improve drug development outcomes, support individualized therapy approaches, and reduce the burden of post-marketing studies and label revisions that currently limit patient access to medications.